Biochemistry laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Alexander Guminski; Peter Foley; Jean-Jacques Grob; Caroline Robert; Ralf  Gutzmer; Nicholas Squittieri; Felix Kiecker

doi:10.25251/skin.7.supp.181

Alexander Guminski

Royal North Shore Hospital; The University of Sydney

Peter Foley

Department of Dermatology, St Vincent’s Hospital Melbourne; The University of Melbourne; Skin Health Institute Inc.

Jean-Jacques Grob

Service de Dermatologie et Cancérologie Cutanée, Hôpital de la Timone, Aix-Marseille Université

Caroline Robert

Department of Dermatology, Institut Gustave Roussy and Paris-Saclay University

Ralf Gutzmer

University Clinic for Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic Minden

Nicholas Squittieri

Sun Pharmaceutical Industries, Inc.

Felix Kiecker

Department of Dermatology, Venereology, and Allergology, Charité Universitätsmedizin Berlin

Keywords

sonidegib, basal cell carcinoma, biochemistry assessments, advanced basal cell carcinoma, Hedgehog pathway inhibitor, oncology

References

1. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

2. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

3. Odomzo (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002839/WC500192970.pdf.

5. Swissmedic, Authorization Number 65065, 2015. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/odomzo--200mg--kapseln--sonidegibum-.html.

6. Australian Government Department of Health, ARTG 292262. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02511-1&d=2018030216114622483.

7. Dummer R, et al. Br J Dermatol. 2020;182(6):1369–78.

8. Dummer R, et al. J Am Acad Dermatol. 2016;75(1):113–25.e115.

9. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

10. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

11. Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

Poster PDF

Published

Mar 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.181

How to Cite

[1]

Guminski, A., Foley, P., Grob, J.-J., Robert, C., Gutzmer, R. , Squittieri, N. and Kiecker, F. 2023. Biochemistry laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s181. DOI:https://doi.org/10.25251/skin.7.supp.181.

Issue

Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®

Section

Skin Cancer

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Georgina V. Long, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Stephan Grabbe, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaëlle Quéreux, Tarek Meniawy, Paolo A. Ascierto, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, John M. Kirkwood, Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Jonathan Silverberg, Thomas Bieber, Amy Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Peter Foley, Erin Johansson, Martin Dossenbach, Bülent Akmaz, Marta Casillas, Andrei Karlsson, Raj Chovatiya, Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley, Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Bruce Strober , Akihiko Asahina, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard Langley, Jonathan Barker, Christopher Cioffi, Nancy Cross, Maggie Wang, Carle Paul, Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Michael Migden, Chrysalyne Schmults, Nikhil Khushalani, Alexander Guminski, Anne Lynn Chang, Karl Lewis, George Ansstas, Samantha Bowyer, Brett Hughes, Dirk Schadendorf, Badri Modi, Lara Dunn, Lukas Flatz, Axel Hauschild, Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy, Matthew Fury, Danny Rischin, Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Kenneth Gordon, Kim Papp, Melinda Gooderham, Akimichi Morita, Peter Foley, Diamant Tha?i, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banergee, BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Alexander Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Martin Kaatz, Karl Lewis, Nicole Basset-Segiun, Anne Lynn Chang, Stephanie Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael Migden, Reinhard Dummer, Siyu Li, Kosalai Mohan, Ebony Coates, Vladimir Jankovic, Nathalie Flaschi, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincent De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, Israel Lowy, Timothy Bowler, Matthew Fury, Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Jonathan Barker, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul, Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley, Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Neil Korman, Kim Papp, Jerry Bagel, Peter Foley, Akimichi Morita, Subhashis Banerjee, Elizabeth Colston, Tao Wang, John Throup, Diamant Thaci, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)